Background/Aim: Docetaxel (DTX) is metabolized by liver cytochromes P450 (CYP) 3A4 (CYP3A4) and 3A5 (CYP3A5) CYP3A4 activity is considered the main factor affecting the effectiveness in DTX clearance. We, therefore, explored the association between DTX-induced febrile neutropenia (FN) and concomitant polypharmacy involving CYP3A4 inhibitors in cancer patients. Patients and Methods: Among patients who received docetaxel, we compared the number of concomitant medications between patients with and without FN, and risk factors associated with FN were identified. Results: The total number of concomitant CYP3A4 inhibitors and substrates used was significantly higher in patients with FN [mean: 2.1 (95% confidence interval (CI)=1.5-2.9)] than in those without FN [mean: 1.4 (95% CI=1.0-1.8)] (p=0.01). The only risk factor for FN was the use of ≥2 concomitant CYP3A4 inhibitors and substrates in total (OR=4.82, 95% CI=1.77-14.1; p=0.002). Conclusion: Polypharmacy involving CYP3A4 inhibitors and substrates increases the risk of DTX-induced FN. Copyright 2021, International Institute of Anticancer Research.
Background/Aim: Docetaxel (DTX) is metabolized by liver cytochromes P450 (CYP) 3A4 (CYP3A4) and 3A5 (CYP3A5) CYP3A4 activity is considered the main factor affecting the effectiveness in DTX clearance. We, therefore, explored the association between DTX-induced febrile neutropenia (FN) and concomitant polypharmacy involving CYP3A4 inhibitors in cancer patients. Patients and Methods: Among patients who received docetaxel, we compared the number of concomitant medications between patients with and without FN, and risk factors associated with FN were identified. Results: The total number of concomitant CYP3A4 inhibitors and substrates used was significantly higher in patients with FN [mean: 2.1 (95% confidence interval (CI)=1.5-2.9)] than in those without FN [mean: 1.4 (95% CI=1.0-1.8)] (p=0.01). The only risk factor for FN was the use of ≥2 concomitant CYP3A4 inhibitors and substrates in total (OR=4.82, 95% CI=1.77-14.1; p=0.002). Conclusion: Polypharmacy involving CYP3A4 inhibitors and substrates increases the risk of DTX-induced FN. Copyright 2021, International Institute of Anticancer Research.
Entities:
Keywords:
CYP3A4; Polypharmacy; docetaxel; drug interaction; febrile neutropenia
Authors: Y-W Lim; B-C Goh; L-Z Wang; S-H Tan; B Y S Chuah; S-E Lim; P Iau; S A Buhari; C-W Chan; N B Sukri; M T Cordero; R Soo; S-C Lee Journal: Ann Oncol Date: 2010-04-29 Impact factor: 32.976
Authors: M E Hamaker; C Seynaeve; A N M Wymenga; H van Tinteren; J W R Nortier; E Maartense; H de Graaf; F E de Jongh; J J Braun; M Los; J G Schrama; A E van Leeuwen-Stok; S M de Groot; C H Smorenburg Journal: Breast Date: 2013-12-05 Impact factor: 4.380
Authors: P Hamberg; R H J Mathijssen; P de Bruijn; C Leonowens; D van der Biessen; F A L M Eskens; S Sleijfer; J Verweij; M J A de Jonge Journal: Cancer Chemother Pharmacol Date: 2014-12-23 Impact factor: 3.333
Authors: Hans Wildiers; Pieter Heeren; Martine Puts; Eva Topinkova; Maryska L G Janssen-Heijnen; Martine Extermann; Claire Falandry; Andrew Artz; Etienne Brain; Giuseppe Colloca; Johan Flamaing; Theodora Karnakis; Cindy Kenis; Riccardo A Audisio; Supriya Mohile; Lazzaro Repetto; Barbara Van Leeuwen; Koen Milisen; Arti Hurria Journal: J Clin Oncol Date: 2014-08-20 Impact factor: 44.544